Literature DB >> 8905396

Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state.

F W Lorey1, J Arnopp, G C Cunningham.   

Abstract

It has been well known for many years that Black Americans are at increased risk for sickle cell disease and that individuals of Mediterranean ancestry are at increased risk for thalassemias. Beyond this, however, complete assessments of the epidemiology of hemoglobinopathies in Americans have been constrained by lack of large enough sample size, incomplete diagnostic work or testing inadequacies, or missing or misleading ethnicity data. California began universal, mandatory screening of all infants born in the state in 1990, and by January 1996, had screened over 3.3 million infants of various ethnic backgrounds. New information is now available on groups at increased risk for disease, as well as carrier status. The overall prevalence of sickle cell disease (all types) remains high in Blacks at 1 per 396 births, but is lower than expected (from east coast/ Caribbean published data) for Hispanics at 1 m 36,000 births or from previously published data on other higher risk groups such as Middle Eastern (no cases in over 22,000 screens) or Asian Indian (1 case in 16,000 screens). The distribution of different types of sickle cell disease has also changed, with increased numbers of Hb SE disease resulting from multiethnic partnerships. Demographic trends in California have led to a major sift in the at-risk groups for major beta thalassemias, with the majority of cases detected in families of Asian, Southeast Asian, and Asian Indian ancestry. The "new" hemoglobinopathy condition in California, Hb E/Beta. Thalassemia, is found almost exclusively in Southeast Asians with a prevalence of 1 in every 2,600 births. Carrier conditions are found in virtually every ethnic category, with higher than expected rates in non-Hispanic Whites (1 per 600 births).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8905396     DOI: 10.1002/(SICI)1098-2272(1996)13:5<501::AID-GEPI6>3.0.CO;2-4

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  32 in total

1.  Thirty-year risk of ischemic stroke in individuals with sickle cell trait and modification by chronic kidney disease: The atherosclerosis risk in communities (ARIC) study.

Authors:  Melissa C Caughey; Vimal K Derebail; Nigel S Key; Alexander P Reiner; Rebecca F Gottesman; Abhijit V Kshirsagar; Gerardo Heiss
Journal:  Am J Hematol       Date:  2019-09-10       Impact factor: 10.047

2.  Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin.

Authors:  Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Mary Kleyn; Kevin J Dombkowski
Journal:  Blood Adv       Date:  2019-05-28

3.  Sickle-cell disease in California: a population-based description of emergency department utilization.

Authors:  Julie A Wolfson; Sheree M Schrager; Thomas D Coates; Michele D Kipke
Journal:  Pediatr Blood Cancer       Date:  2010-11-24       Impact factor: 3.167

4.  Antibiotic Prophylaxis for Children With Sickle Cell Anemia.

Authors:  Sarah L Reeves; Alison C Tribble; Brian Madden; Gary L Freed; Kevin J Dombkowski
Journal:  Pediatrics       Date:  2018-02-05       Impact factor: 7.124

5.  Hydroxyurea Initiation Among Children With Sickle Cell Anemia.

Authors:  Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski
Journal:  Clin Pediatr (Phila)       Date:  2019-05-21       Impact factor: 1.168

6.  Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.

Authors:  Michael R DeBaun; Mae Gordon; Robert C McKinstry; Michael J Noetzel; Desiree A White; Sharada A Sarnaik; Emily R Meier; Thomas H Howard; Suvankar Majumdar; Baba P D Inusa; Paul T Telfer; Melanie Kirby-Allen; Timothy L McCavit; Annie Kamdem; Gladstone Airewele; Gerald M Woods; Brian Berman; Julie A Panepinto; Beng R Fuh; Janet L Kwiatkowski; Allison A King; Jason M Fixler; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Natalia Dixon; Corina E Gonzalez; Karen A Kalinyak; Charles T Quinn; John J Strouse; J Philip Miller; Harold Lehmann; Michael A Kraut; William S Ball; Deborah Hirtz; James F Casella
Journal:  N Engl J Med       Date:  2014-08-21       Impact factor: 91.245

7.  Asthma Screening in Pediatric Sickle Cell Disease: A Clinic-Based Program Using Questionnaires and Spirometry.

Authors:  Sara C Sadreameli; Rachel O Alade; Peter J Mogayzel; Sharon McGrath-Morrow; John J Strouse
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2017-12-01       Impact factor: 1.349

8.  A policy impact analysis of the mandatory NCAA sickle cell trait screening program.

Authors:  Beth A Tarini; Margaret Alison Brooks; David G Bundy
Journal:  Health Serv Res       Date:  2011-12-08       Impact factor: 3.402

9.  Sickle cell trait and incident ischemic stroke in the Atherosclerosis Risk in Communities study.

Authors:  Melissa C Caughey; Laura R Loehr; Nigel S Key; Vimal K Derebail; Rebecca F Gottesman; Abhijit V Kshirsagar; Megan L Grove; Gerardo Heiss
Journal:  Stroke       Date:  2014-08-19       Impact factor: 7.914

10.  The excess burden of stroke in hospitalized adults with sickle cell disease.

Authors:  John J Strouse; Lori C Jordan; Sophie Lanzkron; James F Casella
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.